King of Prussia biopharm firm posts positive study data for experimental pneumonia therapy

Nabriva Therapeutics announced positive results Monday from its second large-scale, late-stage clinical trial of its experimental therapy for community-acquired bacterial pneumonia (CABP). The biopharmaceutical company, which has operations in Dublin, Ireland and King of Prussia, plans to file a new drug application for the therapy – called Lefamulin – with the Food and Drug Administration during the fourth quarter of this year. Nabriva’s stock surged by more than 20 percent in pre-market…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news